Advertisement

Topics

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16:20 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation Committee...

Other Sources for this Article

Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com

NEXT ARTICLE

More From BioPortfolio on "Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...